Myrbetriq ( Mirabegron )
Myrbetriq er Uses:
Prolonged-release tablet. Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
The recommended dose is 50 mg once daily with or without food.The tablet is to be taken once daily, with liquids, swallowed whole and is not to be chewed, divided, or crushed. The safety and efficacy of mirabegron in children below 18 years of age have not yet been established.
ACTIVE: Mirabegron INACTIVE: polyethylene oxide, polyethylene glycol, hydroxypropyl cellulose, butylated hydroxytoluene, magnesium stearate, hypromellose, yellow ferric oxide and red ferric oxide (25 mg only)
Mirabegron has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) and, therefore, it is not recommended for use in patient population with renal impairment. Data are limited in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2),a dose reduction to 25 mg is recommended in this population. Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in this patient population.
COMMON (>1/10): Urinary tract infection, Tachycardia, Nausea. UNCOMMON (>1/100 to <1/10):Vaginal infection, Cystitis, Palpitation, Dyspepsia, Gastritis, Urticaria, Rash, Pruritus, Joint swelling, Vulvovaginal pruritus,Blood pressure increased. RARE: Eyelid oedema, Lip oedema, Leukocytoclastic vasculitis, Purpura, Angioedema.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.